Precautions with oral live typhoid (Ty 21a) vaccine

Wolfe, MartinS.

doi:10.1016/0140-6736(90)93429-s

Cited by 18 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, CQ significantly reduces the vibriocidal antibody response to oral cholera vaccine of Vibrio cholerae CVD103-HgR live oral vaccine whereas CQ can be given at the same time as oral typhoid vaccine without reducing its efficacy [51]. Similarly, the use of CQ with pyrimethamine and sulfadoxine do not affect the immune response to oral typhoid vaccine [52]. CQ significantly reduces intradermal human diploid-cell rabies vaccine [53] and CQ prophylaxis is associated with poor antibody response to this vaccine [54].…”

Section: Vaccinesmentioning

confidence: 99%

“…Another study also indicates that CQ does not adversely affect the antibody response to yellow fever vaccine [56]. CQ does not alter the antibody response to tetanus, diphtheria, measles, oral poliomyelitis, oral typhoid (live), or BCG vaccines [52,57]. Thus, WHO recommends that people currently taking malaria prophylaxis or those unable to complete the 3-dose rabies pre-exposure regime before starting malaria prophylaxis with CQ analogues should receive pre-exposure rabies vaccination [58].…”

Section: Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Clinically Significant Drug Interaction Profiles of Chloroquine Analogues with Adverse Consequences and Risk Management

Al‐Bari¹,

Islam²

2015

J. Sci. Res.

View full text Add to dashboard Cite

The popularity of chloroquine (CQ) analogues, for malaria treatment in many countries emanates from it being cheap, widely available, relatively well tolerated, and having a rapid onset of action. Thus, CQ analogues are commonly sold as over-the-counter (OTC) medications. CQ analogues like hydroxychloroquine (HCQ) alone and/or other drugs in combination have been used as anti-inflammatory and immunomodulatory drugs in the treatment of various rheumatic diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), sarcoidosis, dermatomyositis, Sjögren's syndrome, chronic juvenile arthritis, psoriatic arthritis, and have shown clinical benefits with an acceptable safety profile. As anti-inflammatory mechanism, CQ inhibits pro-inflammatory cytokine release, antigen processing and blocking the actions of histamine and phospholipase A 2 . CQ analogue has also been studied for its potential as an enhancing agent in cancer therapies in various clinical trials. In many cases, the lysosomotrophic property of CQ appears to be important for the increase in efficacy and specificity to inhibit inflammatory disorders. Moreover, it is indicated that the efficacy of conventional therapies can be dramatically enhanced if CQ analogues are given in combination. Although majority of CQ analogue in combination therapies improves overall the outcome, such treatments are often associated with serious toxicities leading to fatal.

show abstract